# Efficacy and Tolerability of Propiverine Hydrochloride in Patients With Neurogenic Detrusor Overactivity

> **NCT01530620** · PHASE3 · COMPLETED · sponsor: **APOGEPHA Arzneimittel GmbH** · enrollment: 66 (actual)

## Conditions studied

- Neurogenic Urinary Bladder Disorder
- Urinary Bladder, Neurogenic
- Bladder Disorder, Neurogenic
- Urinary Bladder Disorder, Neurogenic
- Neurogenic Bladder Disorder
- Urinary Bladder Neurogenic Dysfunction
- Urologic Diseases
- Overactive Detrusor Function
- Urinary Incontinence

## Interventions

- **DRUG:** Propiverine hydrochloride ER (extended release)
- **DRUG:** Propiverine hydrochloride IR (immediate release)

## Key facts

- **NCT ID:** NCT01530620
- **Lead sponsor:** APOGEPHA Arzneimittel GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-12
- **Primary completion:** 2005-06
- **Final completion:** 2006-07
- **Target enrollment:** 66 (ACTUAL)
- **Last updated:** 2012-02-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01530620

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01530620, "Efficacy and Tolerability of Propiverine Hydrochloride in Patients With Neurogenic Detrusor Overactivity". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01530620. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*